Longitudinal Monitoring of Donor-Derived Cell-Free DNA Supports Risk Stratification in Kidney Transplant Recipients With Allograft Dysfunction
Transplant International · 12.03.2026 · 39
DOI: 10.3389/ti.2026.15929 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant International, online erschienen am 12.03.2026. Verfasst von Iris Schröter und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, University Hospital Heidelberg, Heidelberg, Germany. Hauptthemen laut MEDLINE: Kidney Transplantation, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The prognostic value of donor-derived cell-free DNA (dd-cfDNA) for long-term kidney allograft outcomes after indication biopsy remains incompletely defined. In this prospective single-center cohort, 106 kidney transplant recipients with 108 indication biopsies were assessed for dd-cfDNA at biopsy and at 7, 30, and 90 days thereafter. dd-cfDNA was analyzed as a continuous, threshold-based, and longitudinal time-dependent variable. Clinical endpoints included ≥30% eGFR decline within 2 years, indication for re-biopsy, and graft failure. Persistent elevation of dd-cfDNA (≥0.5% at 90 days) occurred in 7.4% of patients, with 50% requiring re-biopsy and 37.5% developing graft failure. A single measurement ≥1.0% significantly predicted ≥30% eGFR decline (HR 2.28; 95% CI 1.03–5.05), whereas levels ≥0.5% were less discriminative. In multivariable time-dependent Cox models adjusted for age, sex, time from transplantation to biopsy, baseline eGFR, baseline proteinuria, and Banff domain scores, longitudinal dd-cfDNA remained independently associated with ≥30% eGFR decline (HR 1.68; 95% CI 1.12–2.51), re-biopsy (HR 1.88; 95% CI 1.38–2.55), and graft failure (HR 3.42; 95% CI 2.00–5.86). In conclusion, dd-cfDNA levels, particularly when assessed longitudinally, are associated with adverse allograft outcomes after indication biopsy and may provide relevant prognostic information beyond a single measurement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, University Hospital Heidelberg, Heidelberg, Germany.
- Department of Transplantation Immunology, University Hospital Heidelberg, Heidelberg, Germany.
- Department of Nephrology and Hypertension, Klinikum Nuremberg, Paracelsus Medical University, Nuremberg, Germany.
Zitieren
APA
Schröter, I., Loi, L., Reineke, M., Rudek, M., Nusshag, C., Kälble, F., Speer, C., Zeier, M., Tran, T. H., Morath, C., & Benning, L. (2026). Longitudinal Monitoring of Donor-Derived Cell-Free DNA Supports Risk Stratification in Kidney Transplant Recipients With Allograft Dysfunction. Transplant International, 39. https://doi.org/10.3389/ti.2026.15929
Vancouver
Schröter I, Loi L, Reineke M, Rudek M, Nusshag C, Kälble F, et al. Longitudinal Monitoring of Donor-Derived Cell-Free DNA Supports Risk Stratification in Kidney Transplant Recipients With Allograft Dysfunction. Transplant International. 2026;39. doi:10.3389/ti.2026.15929
BibTeX
@article{Schrter2026,
author = {Schröter, Iris and Loi, Lisa and Reineke, Marvin and Rudek, Markus and Nusshag, Christian and Kälble, Florian and Speer, Claudius and Zeier, Martin and Tran, Thuong Hien and Morath, Christian and Benning, Louise},
title = {Longitudinal Monitoring of Donor-Derived Cell-Free DNA Supports Risk Stratification in Kidney Transplant Recipients With Allograft Dysfunction},
journal = {Transplant International},
year = {2026},
volume = {39},
doi = {10.3389/ti.2026.15929}
}
EUVIMED